Market Overview - The main indices showed mixed performance today, with the Shanghai Composite Index up by 0.02%, the Shenzhen Component down by 0.7%, and the ChiNext Index down by 1.21% [1] - Among the Shenwan first-level industry sectors, the top performers were comprehensive, public utilities, and real estate, while household appliances, electronics, and food and beverage lagged behind [1] - Concept sectors overall performed well, particularly in continuous boards, board hitting, and pre-increase concepts, whereas generic drugs, medical services, and CRO concepts performed relatively poorly [1]

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector's potential for a reversal in 2025, highlighting innovative drugs and left-side sector recovery as the main investment opportunities [4][44]. Core Insights - The innovative drug sector remains in a high prosperity state, with significant collaborations continuing to emerge. The upcoming 85th American Diabetes Association (ADA) Scientific Sessions in June 2025 is expected to provide important clinical and research updates from endocrine and metabolic drug companies, suggesting investment opportunities in this area [11][44]. - The report emphasizes the increasing approval and quality of new drugs in China, indicating a recovery in the innovative drug sector that has been undervalued for several years. The global recognition of China's technological capabilities is also drawing renewed attention from capital markets towards domestic pharmaceutical companies [27][44]. - The report suggests focusing on leading companies with international expansion and innovation progress, such as Heng Rui Medicine, BeiGene, Innovent Biologics, and others, as well as ADC leaders like Keren Pharmaceutical and Bai Li Tianheng [27][44]. Summary by Sections Pharmaceutical Sector - UroGen Pharma's FDA approval of Zusduri, the first and only drug for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, marks a significant breakthrough in drug delivery systems [20][21]. - The report highlights the progress in chronic disease metabolism, with Eli Lilly's oral Lp(a) lowering drug being considered for breakthrough therapy designation, indicating a growing pipeline of innovative treatments [23][27]. - Merck's oral PCSK9 inhibitor Enlicitide has shown positive results in Phase III trials, representing a significant advancement in cholesterol management therapies [28][29]. Medical Devices - The launch of the MAGLUMI X10, a high-speed automated chemiluminescence immunoassay analyzer, reflects the increasing demand for innovative medical devices in China [33][35]. - The investment by Xianjian Technology in Jianhu Medical to develop electrophysiology products indicates a strategic move to enhance capabilities in high-end medical devices [36][38]. Medical Services - The successful initiation of China's first invasive brain-computer interface clinical trial signifies a major advancement in medical technology, with potential applications for improving the quality of life for patients with spinal cord injuries and amputations [39][40]. - The report anticipates rapid growth in related industries, including high-end imaging equipment and surgical robots, driven by technological advancements and policy support [40]. Traditional Chinese Medicine - The approval of Fangsheng Pharmaceutical's innovative traditional Chinese medicine product marks a significant step in the development of new drugs in this sector, with an expected increase in new drug applications in the coming years [41][43].

Market Overview - The main indices showed slight declines today, with the Shanghai Composite Index down by 0.02%, the Shenzhen Component Index down by 0.26%, and the ChiNext Index down by 0.31% [1] - Among the Shenwan first-level industry sectors, textiles and apparel, environmental protection, and coal performed well, while automotive, real estate, and computer sectors lagged behind [1] - Concept sectors showed mixed performance, with gold and jewelry, dairy, and consecutive board concepts performing relatively well, while CRO, medical services, and near-term new stocks underperformed [1]

2025 年 05 月 13 日 投资要点 分析师：孟之绪 执业编号：S0300524080001 电话： 邮箱：mengzhixu@ykzq.com 证券研究报告 | 策略点评 投资策略研究 粤开市场日报-20250513 今日关注 指数涨跌情况：今日 A 股主要宽基指数涨少跌多。截止收盘，沪指涨 0.17%， 收报 3374.87 点；深证成指跌 0.13%，收报 10288.08 点；创业板指跌 0.12%， 收报 2062.26 点；科创 50 跌 0.15%，收报 1009.68 点。总体上全天个股涨少 跌多，Wind 数据显示，全市场 1940 只个股上涨，3233 只个股下跌，237 只个 股收平。沪深两市今日成交额合计 12915 亿元，较上个交易日缩量约 169 亿 元。 行业涨跌情况：今日申万一级行业涨多跌少，银行、美容护理、医药生物、 交通运输和煤炭行业领涨，涨幅分别为 1.52%、1.18%、0.90%、0.72%和 0.62%， 国防军工、计算机、机械设备、电子和通信行业领跌，跌幅分别为 3.07%、0.80%、 0.66%、0.64%和 0.61%。 板块涨跌情况：今日涨幅居前概念 ...

Investment Rating - The report maintains an optimistic outlook for the pharmaceutical industry in 2025, suggesting a potential for diverse investment opportunities as the sector's valuation is currently low [9][10]. Core Viewpoints - The pharmaceutical sector is expected to experience growth driven by macroeconomic factors and the performance of major products [9]. - The report emphasizes a shift from quantity to quality in the innovative drug sector, highlighting the importance of product differentiation and internationalization [9]. - The medical device sector is witnessing a recovery in bidding volumes and ongoing equipment upgrades, with specific attention on companies like Mindray and Yuyue [9]. - The report identifies a potential rebound in the CXO and life sciences services sector, with expectations of high profit elasticity as companies enter a return-on-investment phase [9]. - The traditional Chinese medicine sector is projected to benefit from policy advantages and market concentration, with specific companies recommended for investment [11]. Summary by Sections Overall Pharmaceutical Industry - In 2024, the pharmaceutical sector's comparable company revenue decreased by 0.9%, with a net profit decline of 8.5% [16]. - The medical device sector showed the highest revenue growth among sub-sectors, while traditional Chinese medicine faced the most significant revenue decline [16]. Innovative Drugs - The innovative drug sector's revenue for 2024 is projected at 565.3 billion, a 34.1% increase from the previous year, with several companies achieving profitability for the first time [18][19]. - The report highlights the increasing number of IND and NDA approvals for domestic innovative drugs, indicating a growing presence in international markets [19]. Medical Devices - The medical device sector is experiencing a recovery in bidding volumes, with a focus on imaging equipment and home medical devices [9]. - The report notes that the orthopedic and neurosurgery fields are seeing improved growth post-collection, with significant attention on companies like Aikang and Weili [9]. Traditional Chinese Medicine - The report anticipates a market rebound for essential medicines, with specific companies recommended for investment based on their unique product offerings and market positioning [11]. Retail and Distribution - The report expresses confidence in the retail pharmacy sector, driven by prescription outflow and an improving competitive landscape [11]. Medical Services - The report suggests that the medical services sector will benefit from anti-corruption measures and the expansion of commercial insurance, enhancing the competitiveness of private healthcare providers [11]. Blood Products - The blood products sector is expected to see growth due to relaxed approval processes and increased demand post-pandemic, with companies like Tiantan Biological and Boya Biological highlighted for their potential [11].

Market Overview - The A-share market showed mixed performance today, with the Shanghai Composite Index down by 0.05% closing at 3286.65 points, and the Shenzhen Component Index also down by 0.05% closing at 9849.80 points. The ChiNext Index fell by 0.13% to 1931.94 points. Overall, 3556 stocks rose while 1670 stocks fell, with a total trading volume of 10221 billion yuan, a decrease of approximately 34.2 billion yuan from the previous trading day [1][13]. Industry Performance - Among the Shenwan first-level industries, the leading sectors included Beauty Care, Machinery Equipment, Media, Light Industry Manufacturing, and Basic Chemicals, with respective gains of 2.60%, 1.44%, 1.27%, 1.04%, and 0.87%. Conversely, the sectors that experienced declines included Utilities, Comprehensive, Oil & Petrochemicals, Coal, and Social Services, with respective losses of 1.78%, 0.97%, 0.55%, 0.51%, and 0.47% [1][13]. Concept Sector Performance - The top-performing concept sectors today were Animal Vaccines, Marketing Communication, Medical Beauty, Auto Parts, Chemical Fibers, and Virtual Reality, among others. These sectors showed significant upward movement, while sectors like Electricity, Baijiu, and Insurance experienced pullbacks [2][11].